NASDAQ:ACTU Actuate Therapeutics 5/15/2025 Earnings Report $6.23 +0.26 (+4.36%) Closing price 04:00 PM EasternExtended Trading$6.26 +0.02 (+0.40%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Actuate Therapeutics EPS ResultsActual EPS-$0.32Consensus EPS -$0.26Beat/MissMissed by -$0.06One Year Ago EPSN/AActuate Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AActuate Therapeutics Announcement DetailsQuarterDate5/15/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Actuate Therapeutics Earnings HeadlinesActuate Therapeutics, Inc.June 30, 2025 | cnn.comActuate Therapeutics Reports Promising Survival Outcomes in Phase 2 Trial of Elraglusib for Metastatic Pancreatic Cancer - NasdaqJune 26, 2025 | nasdaq.comThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump could be just weeks away. And it holds the potential to trigger one of the most explosive tech booms in US history. At the center of it all? Robots. Not the kind that clean your house or pour you coffee. But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year.July 16 at 2:00 AM | Weiss Ratings (Ad)Myelofibrosis Market Poised for Strong Growth, Fueled by FDA Designations and Promising Clinical Outcomes | DelveInsightJune 24, 2025 | theglobeandmail.comActuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib TrialJune 24, 2025 | globenewswire.comActuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCOJune 20, 2025 | globenewswire.comSee More Actuate Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Actuate Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Actuate Therapeutics and other key companies, straight to your email. Email Address About Actuate TherapeuticsActuate Therapeutics (NASDAQ:ACTU), headquartered in Irvine, California, is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies targeting hormone-driven pathways and DNA damage repair mechanisms in oncology. The company leverages proprietary formulation technologies and deep scientific expertise to create treatments aimed at improving outcomes for patients with advanced cancers. The company’s lead asset, onapristone extended release (ONA-XR), is an oral selective progesterone receptor antagonist designed to block progesterone-driven tumor growth. ONA-XR is being evaluated in multiple clinical trials, including studies in metastatic breast cancer and endometrial carcinoma. In addition to ONA-XR, Actuate is advancing a pipeline of earlier-stage programs that focus on modulating DNA damage response pathways, with the goal of addressing treatment resistance and enhancing precision therapy options. Since its founding in 2016, Actuate Therapeutics has pursued strategic collaborations with academic institutions and clinical research sites across North America and Europe. The company’s management team, led by President and Chief Executive Officer Mark McCamish, Ph.D., brings together extensive experience in oncology drug development, regulatory strategy and commercialization planning. Actuate remains committed to translating scientific innovation into meaningful therapeutic advances for patients with high-unmet-need cancers.Written by Jeffrey Neal JohnsonView Actuate Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportSmith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still Strong Upcoming Earnings Cintas (7/17/2025)Interactive Brokers Group (7/17/2025)Netflix (7/17/2025)PepsiCo (7/17/2025)Abbott Laboratories (7/17/2025)Elevance Health (7/17/2025)GE Aerospace (7/17/2025)American Noble Gas (7/17/2025)Marsh & McLennan Companies (7/17/2025)Novartis (7/17/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
